Clonal Architecture of ASXL1-mutated Myelofibrosis
Key claim: A prospective study characterizes the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and demonstrates its prognostic significance.
Abstract
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis
Why this matters
ASXL1 is one of the most consistently adverse molecular lesions across myelofibrosis (both primary and post-PV/post-ET secondary forms), but its clonal architecture — whether dominant/founder vs subclonal, and its co-mutation context — has been incompletely defined prospectively. By linking clonal hierarchy to outcome, this finding refines subtype-specific prognostication in PMF beyond simple presence/absence of ASXL1 and may inform risk-adapted decisions about transplant timing and trial enrollment.